Daily Respiratory Research Analysis
A phase 3 randomized trial showed that early add-on sotatercept significantly reduced clinical worsening in newly diagnosed pulmonary arterial hypertension. A Nature Immunology study using pDC-less mice challenged the dogma that plasmacytoid dendritic cells are essential for antiviral defense in respiratory infections, suggesting they may even worsen lung immunopathology. A meta-analysis of mesenchymal stem/stromal cell–based therapies for ARDS indicated reduced short-term mortality with accepta
Summary
A phase 3 randomized trial showed that early add-on sotatercept significantly reduced clinical worsening in newly diagnosed pulmonary arterial hypertension. A Nature Immunology study using pDC-less mice challenged the dogma that plasmacytoid dendritic cells are essential for antiviral defense in respiratory infections, suggesting they may even worsen lung immunopathology. A meta-analysis of mesenchymal stem/stromal cell–based therapies for ARDS indicated reduced short-term mortality with acceptable safety, underscoring the need for larger rigorous trials.
Research Themes
- Early disease-modifying therapy in pulmonary arterial hypertension
- Innate immune mechanisms in respiratory viral infections
- Cell-based and extracellular vesicle therapies in ARDS
Selected Articles
1. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
In a multicenter phase 3 RCT of 320 adults with PAH diagnosed within the prior year, add-on sotatercept reduced time to clinical worsening versus placebo (HR 0.24) on top of double/triple background therapy. Benefits were driven by fewer exercise test deteriorations and PAH hospitalizations; adverse events included epistaxis and telangiectasia.
Impact: This is a high-quality phase 3 RCT demonstrating early disease-modifying benefit of sotatercept in PAH, a condition with high morbidity and mortality. Findings are likely to influence guideline recommendations regarding early add-on therapy.
Clinical Implications: For PAH within one year of diagnosis, consider adding sotatercept to optimized background therapy in WHO FC II–III with intermediate/high risk, with monitoring for epistaxis/telangiectasia and hematologic effects. Earlier initiation may reduce hospitalizations and functional decline.
Key Findings
- Primary endpoint events: 10.6% with sotatercept vs 36.9% with placebo (HR 0.24; 95% CI 0.14–0.41; P<0.001).
- Exercise test deterioration: 5.0% vs 28.8%; unplanned PAH hospitalization: 1.9% vs 8.8% (sotatercept vs placebo).
- Adverse events: epistaxis (31.9%) and telangiectasia (26.2%) were most common with sotatercept.
Methodological Strengths
- Randomized, placebo-controlled, multicenter phase 3 design with time-to-event primary endpoint.
- Contemporary background double/triple therapy and prespecified composite clinical worsening outcome.
Limitations
- Early trial termination may overestimate effect size and limits long-term safety assessment.
- Mortality events were few and similar across groups; no atrial septostomy or transplantation occurred.
Future Directions: Assess long-term outcomes, optimal sequencing with other PAH therapies, and real-world effectiveness/safety in broader populations including WHO FC IV. Explore biomarkers to guide sotatercept initiation.
BACKGROUND: Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial hypertension within the first year after diagnosis are unclear. METHODS: In this phase 3 trial, we enrolled adult patients with World Health Organization functional class II or III pulmonary arterial hypertension who had received the diagnosis less than 1 year earlier, had an intermediate or high risk of death, and were receiving double or triple background therapy. Patients were randomly assigned to receive add-on therapy with subcutaneous sotatercept (starting dose, 0.3 mg per kilogram of body weight; escalated to target dose, 0.7 mg per kilogram) or placebo every 21 days. The primary end point was clinical worsening, a composite of death from any cause, unplanned hospitalization lasting at least 24 hours for worsening of pulmonary arterial hypertension, atrial septostomy, lung transplantation, or deterioration in performance in exercise testing due to pulmonary arterial hypertension, assessed in a time-to-first-event analysis. RESULTS: The trial was stopped early owing to loss of clinical equipoise after the reporting of positive results from previous sotatercept trials. A total of 320 patients were included (160 each in the sotatercept and placebo groups). The median duration of follow-up was 13.2 months. At least one primary end-point event occurred in 17 patients (10.6%) in the sotatercept group and in 59 patients (36.9%) in the placebo group (hazard ratio, 0.24; 95% confidence interval, 0.14 to 0.41; P<0.001). Deterioration in performance in exercise testing due to pulmonary arterial hypertension occurred in 8 patients (5.0%) in the sotatercept group and in 46 patients (28.8%) in the placebo group; unplanned hospitalization for worsening of pulmonary arterial hypertension occurred in 3 patients (1.9%) and 14 patients (8.8%), respectively; and death from any cause occurred in 7 patients (4.4%) and 6 patients (3.8%). No cases of atrial septostomy or lung transplantation occurred. The most common adverse events with sotatercept were epistaxis (31.9%) and telangiectasia (26.2%). CONCLUSIONS: Among adults with pulmonary arterial hypertension who had received the diagnosis less than 1 year earlier, the addition of sotatercept to background therapy resulted in a lower risk of clinical worsening than placebo. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; HYPERION ClinicalTrials.gov number, NCT04811092.).
2. Plasmacytoid dendritic cells are dispensable or detrimental in murine systemic or respiratory viral infections.
Using a genetically precise pDC-less mouse model, the study shows that pDCs are not required for antiviral protection and can exacerbate lung immunopathology during influenza and SARS-CoV-2 infections. The work overturns a longstanding assumption about pDC indispensability in respiratory viral defense.
Impact: This mechanistic study challenges a key immunological paradigm with direct relevance to respiratory viral infections, informing therapeutic strategies that target interferon pathways and pDCs.
Clinical Implications: Caution is warranted for therapies aiming to boost pDC-derived interferons in influenza or COVID-19, as reducing pDC-driven immunopathology may benefit some patients. Translational studies should stratify by disease phase and immune phenotype.
Key Findings
- Engineered pDC-less mice lacking Siglech/Pacsin1-defined pDCs retained protective immunity to systemic MCMV infection.
- In intranasal influenza and SARS-CoV-2 infection, pDC-less mice had higher survival and reduced lung immunopathology versus controls.
- Results indicate pDC-derived interferons are dispensable or deleterious in several viral infections.
Methodological Strengths
- Creation of a highly specific, constitutive pDC ablation model avoiding off-target effects seen with prior approaches.
- Use of multiple respiratory/systemic viral infection models (influenza, SARS-CoV-2, MCMV) to demonstrate generalizability.
Limitations
- Findings are preclinical in mice; translation to human disease requires validation.
- Specific viral strains, inoculum, and timing may influence outcomes; mechanistic dissection of downstream pathways is needed.
Future Directions: Human translational studies assessing pDC activity and interferon signatures across respiratory viral infection stages; interventional trials modulating pDC responses in hyperinflammatory phenotypes.
Plasmacytoid dendritic cells (pDCs) are major producers of type I/III interferons. As interferons are crucial for antiviral defense, pDCs are assumed to play an essential role in this process; however, robust evidence supporting this dogma is scarce. Genetic or pharmacological manipulations that eliminate pDCs or disrupt their interferon production often affect other cells, confounding interpretation. Here, to overcome this issue, we engineered pDC-less mice that are specifically and constitutively devoid of pDCs by expressing diphtheria toxin under coordinated control of the Siglech and Pacsin1 genes, uniquely coexpressed in pDCs. pDC-less mice mounted protective immunity against systemic infection with mouse cytomegalovirus and showed higher survival and less lung immunopathology to intranasal infection with influenza virus and SARS-CoV-2. Thus, contrary to the prevailing dogma, we revealed that pDCs and their interferons are dispensable or deleterious during several viral infections. pDC-less mice will enable rigorously reassessing the roles of pDCs in health and disease.
3. Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis.
Across 31 studies synthesized from 48 eligible trials (1,773 patients), MSCs and their EV/secretome products significantly reduced all-cause mortality within one month in ARDS (RR 0.74) with low heterogeneity and acceptable safety. Effects beyond one month were not demonstrated.
Impact: This synthesis provides the most comprehensive clinical summary to date suggesting short-term survival benefit of MSC-based interventions in ARDS, guiding trial design and translational efforts.
Clinical Implications: MSC/EV therapies should remain investigational but may be prioritized in trials for severe ARDS with early administration and standardized dosing/characterization. Current evidence does not yet support routine clinical use.
Key Findings
- Meta-analysis (31 studies) showed reduced all-cause mortality within one month with MSC/EV/secretome vs standard care (RR 0.74; 95% CI 0.62–0.89; I²=0–5%).
- No consistent mortality benefit beyond one month was demonstrated.
- Safety was acceptable with no excess serious adverse events reported across studies.
Methodological Strengths
- Pre-registered (PROSPERO) systematic review with broad database coverage and subgroup analyses.
- Low heterogeneity for primary short-term mortality outcome and inclusion of EV/secretome modalities.
Limitations
- Many included trials were small and nonrandomized; heterogeneity in cell sources, dosing, and timing.
- Evidence of benefit confined to short-term mortality; potential publication bias cannot be excluded.
Future Directions: Conduct adequately powered, multicenter RCTs with standardized cell/EV characterization, dosing, and early administration windows, and evaluate longer-term outcomes and patient-centered endpoints.
BACKGROUND: Although numerous clinical trials have explored stem cell-based therapies for acute respiratory distress syndrome (ARDS), their findings are inconsistent. This meta-analysis aimed to comprehensively evaluate the efficacy and safety of stem cell-based therapies, including mesenchymal stem/stromal cells (MSCs) and their derived extracellular vesicles (EVs), in the treatment of ARDS. METHODS: A comprehensive literature search of the Cochrane Library, PubMed, and Web of Science databases and the US National Institutes of Health Trials Registry (ClinicalTrials.gov) was conducted to identify eligible studies assessing the efficacy and safety of stem cell-based therapies in ARDS. The primary outcomes included all-cause mortality within or over one month, adverse events (AEs), and serious adverse events (SAEs). To explore possible bias, subgroup analysis was performed based on the design of study (randomized controlled trial vs. nonrandomized interventional trial), etiology of ARDS, type of stem cell-based therapy, and times of infusion. Relative risk (RR) and mean difference (MD) were calculated to evaluate efficacy and safety. This study was registered with PROSPERO (CRD42024593740). RESULTS: A total of 48 studies involving 1,773 patients were eligible, of which 31 studies were included in the meta-analysis. The results revealed a significant reduction in all-cause mortality among patients receiving MSCs or their derived EVs and secretomes compared to those receiving routine therapy (RR = 0.74, 95% CI = 0.63-0.87, p = 0.0003, I²=5%). This effect was only seen in all-cause mortality within one month (RR = 0.74, 95% CI = 0.62-0.89, p = 0.002, I²=0%); furthermore, high dose MSCs (over 1 × 10 CONCLUSIONS: Stem cell-based therapy significantly reduced mortality within one month and was well tolerated in ARDS patients. Given the limited sample size of included studies, the efficacy of stem cell-based therapy in patients with ARDS needs to be validated in further larger and more rigorous randomized controlled trials.